June 2012

Contents

Editorial

• Volume 13 Number 5/6 May/June 2012

Conference reports

• 18th Annual BHIVA Conference, 18-20 April 2012, UK

• Half of gay men in London would chose oral PrEP to reduce risk of HIV

• Recent infection is common in UK; 30% gay men aged 15-25 infected within a year of diagnosis

• One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated

• Hodgkin’s lymphoma: survival normalises to HIV negative rates despite more advanced disease at diagnosis

• Promising outcomes from laser ablative treatment of AIN2/3 to prevent anal cancer

• KS in the HAART era includes patients with high CD4 and suppressed viral load: importance of KS chemotherapy for some patients in addition to ART

• 3rd vs 4th generation HIV testing: almost half of UK clinics out of step with national guidelines

• Case reports of complications from ketamine use in two MSM on ritonavir-based combinations

• Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations

• Outcomes from switches to atazanavir/r in London

• Intimate partner violence towards HIV positive women in the UK

• 13th International workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2012, Barcelona

• Studies on pipeline ARVs

• Washout pharmacokinetics of transplacental raltegravir in neonates

• Interactions between malaria drugs and etravirine or darunavir/r

• No interaction between antimalarial amodiaquine and nevirapine

• Pharmacokinetics of atazanavir/ritonavir plus raltegravir

• Atazanavir/ritonavir and voriconazole not to be coadministered

• Milk thistle (silymarin) and darunavir/ritonavir

• Echinacea and etravirine

• Warfarin and ARVs: impact of African American race and ritonavir

• 19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012, Seattle

• HIV and the brain: longitudinal results from CHARTER and other studies

• Systolic blood pressure and risk of myocardial infarction in HIV infection

• Risk of non-AIDS defining malignancies and immune suppression

• Renal impairment in the D:A:D study

• Early data for rilpivirine long acting formulation supports further investigation for PrEP

• Hormonal contraception: HIV transmission and progression rates

• Darunavir use during pregnancy

Antiretrovirals

• Fosamprenavir paediatric dosing approved in US for ages 4 weeks to <6 years

• FDA advisory panel vote 13:1 for approval of Quad

• FDA advisory hearing supports approval of tenofovir/FTC for PrEP

Treatment access

• Stavudine (d4T) phase-out festival in Delhi

• FDA approval of generic ARVs: nevirapine and Combivir now off-patent in the US

Pregnancy

• New UK guidelines: Management of HIV infection in pregnant women (2012)

Guidelines

• New UK guidelines: Treatment of HIV-1 positive adults with antiretroviral therapy (2012)

• WHO guidelines for testing, counselling and treatment in serodifferent couples (April 2012): ART at CD4 >350 to reduce transmission

• NICE guideline on fertility treatment proposes alternatives to sperm washing (2012)

Side effects

• 20% people switch Atripla due to efavirenz side effects: late switches are common

• Risk factors associated with End Stage Renal Disease (ESRD) in HIV positive patients in the US Veterans Association (VA) cohort

• Associations between tenofovir use and renal complications in VA cohort

Other news

• ACT-UP at 25: tax Wall Street, end AIDS

PDFs

• Volume 13 Number 5/6 May/June 2012 PDF